Goodfellow Unit Webinar: Empagliflozin for heart failure with reduced ejection fraction

Gerry Wilkins (Consultant Cardiologist) discusses Sodium-glucose co-transporter 2 (SGLT2) inhibitor empagliflozin (the only funded one In New Zealand) that is now available for patients with reduced ejection fraction. Chapters: 00:00 Intro 01:27 Presentation - HFrEF overview 21:46 Audience Q&A 24:59 Presentation Case Study - empagliflozin 35:19 Audience Q&A 49:24 Presentation Clinical Scenarios - Practical considerations 53:35 Audience Q&A 54:46 Presentation 01:05:03 Audience Q&A 01:08:08 Outro